Pharma BD Deal Intelligence
AbbVie grew from $33B to $56B revenue; Allergan Aesthetics + Skyrizi/Rinvoq offset Humira
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
AbbVie Inc. and Allergan plc today announced that the companies have entered into a definitive transaction agreement under which AbbVie will acquire Allergan…
Following divestitures in January, the FTC approved AbbVie's acquisition on May 5, and only one day later the High Court of Ireland also sanctioned the deal.…
FY2025: Vraylar $3.621B; Botox Therapeutic $3.769B; Aesthetics Portfolio $4.860B (-6.1%); Botox Cosmetic $2.602B; total company $61.160B (+8.6%).
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
AbbVie acquired Allergan in a $63 billion cash-and-stock transaction, diversifying its portfolio beyond Humira into aesthetics (Botox), neuroscience, and eye care, creating a combined revenue base of approximately $50 billion.
AbbVie grew from $33B to $56B revenue; Allergan Aesthetics + Skyrizi/Rinvoq offset Humira
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Allergan plc (this deal) | 2019 | $63.0B | 60 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2019 deals · AbbVie Inc. deals · Gastroenterology deals